Two recent studies published this week assess the low uptake of respiratory syncytial virus (RSV) vaccine among US veterans ...

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private sector, but not yet in public clinics. The country’s advisory group on ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory ...

Winter is here, and with it come higher rates of respiratory illnesses. If you've been struck down recently with a sore ...

Babies born very prematurely will be offered protection against respiratory syncytial virus (RSV) with a long-acting antibody ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...

Sanofi has announced that it will be expanding its respiratory vaccines pipeline by acquiring UK-based Vicebio for up to ...